SCHEMBL15466880

SCHEMBL15466880

CCN(CCNC)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.50
APP P05067 3/20 0.49
KDM4E B2RXH2 1/20 0.49
CNR2 P34972 1/20 0.49
ATM Q13315 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
CHRM2 P08172 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
CHRM1 P11229 1/20 0.47
DRD1 P21728 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
DRD3 P35462 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16081620 0.90 ATM (0.54) KDM4ECNR2ATMTAAR1TSHR
SCHEMBL11402252 0.87 HRH3 (0.53) CNR2ATMTAAR1TSHRBCHE
SCHEMBL8250771 0.85 HRH3 (0.48) KDM4EOPRM1
SCHEMBL11401891 0.84 MAPT (0.53) ATMTAAR1CHRM2HTR1AADRA2A
SCHEMBL8079472 0.84 MAOB (0.49) MAOBAPPKDM4ECNR2TSHR
SCHEMBL20067552 0.82 HTT (0.50) APPKDM4EATMTAAR1TSHR
SCHEMBL21969730 0.82 CARM1 (0.53) KDM4ECNR2ATMTAAR1TSHR
SCHEMBL2538898 0.82 MEN1 (0.53) MAOBAPPKDM4ECNR2TSHR
SCHEMBL22749466 0.82 MAOB (0.57) MAOBKDM4ECNR2TSHRMAPK1
SCHEMBL28081581 0.82 ATM (0.58) KDM4ECNR2ATMTAAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393794-B1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS UNIV ILLINOIS (US) 2017-03-22 EP disclosed
EP-2678349-B1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2016-01-13 EP disclosed
US-9139609-B2 C-4″ position substituted macrolide derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-22 US disclosed
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MRPL21, MRPS34, MRPL37 MAOB 2631/4885APP 4851/4885KDM4E 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.